Chennai, India – Shanghai MicroPort Medical Group Co., Ltd. ("MicroPort®") recently attended the annual INDIA LIVE 2018 in India to display its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
During the meeting, a live case of Firehawk® was broadcasted to demonstrate its clinical performance. The operation was conducted by Dr. S.Mullasari Ajit of India-based hospital The Madras Medical Mission to treat a 57-year-old male patient with diabetes and unstable angina pectoris. He had been implanted a stent in the right coronary artery and was again admitted to hospital due to vascular restenosis. Dr. S.Mullasari Ajit predilated the lesion and successfully implanted a 3.5*18mm Firehawk® in the lesion. The postoperative OCT shows excellent outcome and the outstanding pushability and crossability of Firehawk® were highly recognized by physicians and experts in attendance.
During the meeting, several renowned cardiologists including Professor Upendra Kaul of Escorts Heart Institute and Dr. Anil Kumar of Aster Medicity Hospital visited MicroPort® booth and had in-depth discussion regarding the clinical performance of MicroPort® products with Dr. Linda Lin, MicroPort® First Vice President of International Business.
India has the third largest amount of PCI cases in the world, and the market has been experiencing rapid development in recent years. During this meeting, MicroPort® took the opportunity to enhance communications with local experts and demonstrated its strength and growth potential to them. As Firehawk® and Firefighter™ PTCA Balloon Catheter ("Firefighter™") have been gaining higher recognition among local patients and physicians, MicroPort® is enlarging its influence and market share in the India market. In the future, MicroPort® will further expand the India market to provide ideal medical solutions for local patients suffering from cardiovascular diseases.